作者: Aleksandra Pawlak , Justyna Kutkowska , Bożena Obmińska-Mrukowicz , Andrzej Rapak
DOI: 10.1016/J.RVSC.2017.09.026
关键词: Oncology 、 Lymphoma 、 Internal medicine 、 Cancer 、 Canine Lymphoma 、 Medicine 、 Chemotherapy 、 Antimetabolite 、 Methotrexate 、 Canine Leukemia 、 Leukemia
摘要: Methotrexate is an antimetabolite used in the treatment of cancer and non-malignant diseases including rheumatoid arthritis, psoriasis graft vs. host disease. Combination therapy with methotrexate was successful canine lymphoma, mammary tumor invasive urinary bladder cancer. Lymphoma, most common hematopoietic dogs, leukemia are sensitive to chemotherapy, which why may be important option for these diseases. Although already veterinary oncology its effects on cells has not been tested. The aim study evaluate first time concentration-dependent cytotoxicity capability inducing apoptosis selected lymphoma/leukemia cell lines: CLBL-1, GL-1 CL-1 as a step before vitro development new therapeutic options use methotrexate.Methotrexate exhibited inhibitory effect proliferation all examined lines different degree induction. belonged line derived from T neoplasia previously characterized by high resistance majority anticancer drugs dogs. Canine lymphoma methotrexate, this drug useful effective neoplasms especially T-type leukemia/lymphoma.